LOGO
LOGO

Article Search

Discover the power of RTTNews website's advanced search page, designed for seamless Article retrieval by Company Name, Stock Symbol, and other criteria.
Stay updated with the Latest News on specific Companies, Financial Insights, and Market Trends. We Ensure you to get the most relevant information instantly.

Symbol  
Company  
Currency Symbol   eg (EUR/USD)
Keyword  
  • William Blair Is Increasing ARS Pharmaceuticals, Inc. (SPRY) FY24 Rev. Estimate To 4.68 M From 2.68 M 5/10/2024 8:19:05 AM
  • William Blair Is Lowering ARS Pharmaceuticals, Inc. (SPRY) FY25 Estimate To -0.65 From -0.46 5/10/2024 8:18:33 AM
  • William Blair Is Lowering ARS Pharmaceuticals, Inc. (SPRY) FY24 Estimate To -0.69 From -0.57 5/10/2024 8:18:19 AM
  • ARS Pharma Submits Response For Neffy MAA To EMA's CHMP; Enters License Agreement With CSL Seqirus 4/30/2024 9:12:10 AM
  • ARS Pharma Submits Response To FDA Complete Response Letter For Neffy 4/3/2024 9:37:22 AM
  • Wedbush Reiterates ARS Pharmaceuticals, Inc. (SPRY) At Outperform With $19 Price Target 3/11/2024 10:33:23 AM
  • ARS :neffy Meets Primary Endpoints & Shows Rapid Symptom Control In Phase 2 Urticaria Clinical Study 2/26/2024 9:12:24 AM
  • Wedbush Reiterates ARS Pharmaceuticals, Inc. (SPRY) At Outperform With $19 Price Target 2/21/2024 5:32:27 PM
  • ARS Announces Results From Repeat Dosing Study Of Neffy Under Nasal Allergen Challenge Conditions 2/20/2024 10:09:41 AM
  • Wedbush Reiterates ARS Pharmaceuticals, Inc. (SPRY) At Outperform With $13 Up From $5 Price Target 11/13/2023 10:00:10 AM
  • William Blair Is Increasing ARS Pharmaceuticals, Inc. (SPRY) FY24 Estimate To -0.74 From -0.90 11/10/2023 8:41:12 AM
Copyright © 2026 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service. About Us   |   Contact Us   |   Privacy   |   Sitemap